Related Experiment Video
Updated: May 17, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
A comparative analysis of outpatient costs in HIV treatment programs
Flavia Mori Sarti1, Marislei Nishijima, Antonio Carlos Coelho Campino
1Faculdade de Economia, Administração e Contabilidade da Universidade de São Paulo (FEA-USP), São Paulo, SP, Brazil. flamori@usp.br
Insights
The cost of human immunodeficiency virus (HIV) outpatient treatment in Brazil
Area of Science:
- Health Economics
- Public Health Policy
- Infectious Disease Management
Background:
- Human immunodeficiency virus (HIV) treatment costs vary significantly across healthcare systems.
- Understanding cost drivers is crucial for efficient resource allocation in public health programs.
Purpose of the Study:
- To analyze the outpatient treatment costs for HIV in Brazil's public health system, stratified by CD4 cell counts.
- To compare these costs with those in other national health systems globally.
Main Methods:
- A retrospective survey of five public HIV outpatient clinics in São Paulo, Brazil.
- Data collection from medical records for one year of HIV outpatient treatment.
- Market research and public databases for input prices; literature review for international cost data.
Main Results:
- The average annual cost of HIV outpatient treatment in Brazil was US$2,572.92 (2006).
- Costs ranged from US$1,726.19 (CD4 > 500) to US$3,693.28 (51 < CD4 < 200).
- Antiretrovirals (ARVs) constituted 62% of annual costs; private sector treatment was more expensive internationally.
Conclusions:
- Key cost drivers include ARVs, other medications, professional services, and diagnostic exams.
- Health system efficiency influences the magnitude of cost drivers.
- Findings offer valuable insights for evaluating global HIV treatment programs and informing public policy.
Objective:
To analyze the costs of human immunodeficiency virus (HIV) outpatient treatment for individuals with different CD4 cell counts in the Brazilian public health system, and to compare to costs in other national health systems.
Methods:
A retrospective survey was conducted in five public outpatient clinics of the Brazilian national HIV program in the city of São Paulo. Data on healthcare services provided for a period of one year of HIV outpatient treatment were gathered from randomly selected medical records. Prices of inputs used were obtained through market research and public sector databases. Information on costs of HIV outpatient treatment in other national health systems were gathered from the literature. Annual costs of HIV outpatient treatment from each country were converted into 2010 U.S. dollars.
Results:
Annual cost of HIV outpatient treatment for the Brazilian national public program was US$ 2,572.92 in 2006 in São Paulo, ranging from US$ 1,726.19 for patients with CD4 cell count > 500 to US$ 3,693.28 for patients with 51 < CD4 cell count < 200. Antiretrovirals (ARVs) represented approximately 62.0% of annual HIV outpatient costs. Comparing among different health systems during the same period, HIV outpatient treatment presented higher costs in countries where HIV treatment is provided by the private sector.
Conclusion:
The main cost drivers of HIV outpatient treatment in different health systems were: ARVs, other medications, health professional services, and diagnostic exams. Nevertheless, the magnitude of cost drivers varied among HIV outpatient treatment programs due to health system efficiency. The data presented may be a valuable tool for public policy evaluation of HIV treatment programs worldwide.
Related Concept Videos
Retrovirus Life Cycles
Comparing the Survival Analysis of Two or More Groups
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
